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The power of cancer immune surveillance has been documented beyond doubt, and 
the successful exploitation of immune response to cancer has started a new era in the 
war against cancer. Cancer biologists have recognized immunoevasion as an emerg-
ing hallmark in addition to the six hallmarks of cancer. Besides the natural connection 
between the immune system and cancer development, most established environmental 
risk factors are now known to interfere with immune surveillance mechanisms. Genetic 
variations regulating immunity may also modulate cancer susceptibility, but evidence for 
this is currently limited. Molecular cross talk linking “immune” and “genomic” surveillance 
pathways has been characterized. It appears that immune mechanisms may contrib-
ute to the effects of common cancer risk factors. We provide an updated overview 
of evidence for cancer immune surveillance, cancer risk factors interfering with it, and 
interventions to enhance cancer immune surveillance as tools to complement ongoing 
vaccine development efforts for cancer immunoprevention. Although there is a lot of 
support for cancer immunoprevention with simple lifestyle modifications from observa-
tional studies, there is an urgent need for clinical trials to establish the effectiveness of 
this approach for public health benefits.
Keywords: cancer prevention, cancer immunology, cancer immune surveillance, immunoprevention, public 
health, cancer risk factors
iNTRODUCTiON
Cancer is a major global public health issue. The global burden is continuing to increase and pro-
jected to reach 24 million in 2035 from 14 million new cases in 2012 (1). While major progress has 
been made in treatment, prevention remains to be the priority (1). Cancer prevention may benefit 
from the advances in cancer immunotherapy, which has led to the wider acceptance of the original 
idea of cancer immune surveillance. Indeed, the human body is not defenseless against cancer (2). 
The defense is provided by immune system and genomic surveillance mechanisms.
The original cancer immune surveillance concept was formulated almost half a century ago by 
Thomas (3) and Burnet (4, 5) [earlier studies are reviewed in Ref. (6–10)]. The cancer immune 
surveillance has now evolved into the cancer immunoediting concept (11), but for the exclusive 
consideration of cancer prevention, cancer immune surveillance is still a valid notion. The central 
theme of this idea was that an immune response can eliminate cells while they are still in the preclini-
cal stages of transformation to overt cancer.
Given the prominent effect of immunotherapy in cancer treatment, and increasingly more 
widely accepted notion of cancer immune surveillance in cancer prevention (12–14), we explored 
potential connections between general cancer risk factors and immune capacity to examine 
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whether the immune system may be a mediator for cancer risk. 
We also explored whether genetic epidemiology can be used 
as a probe for disease biology by checking genetic associations 
between immune system gene variant and cancer susceptibility. 
We review modifiable and non-modifiable lifestyle factors that 
influence the immune system and may be considered for cancer 
prevention.
iMMUNe SYSTeM iS iNSTRUMeNTAL iN 
CANCeR PReveNTiON
The relationship of the immune system to surveillance of cancer 
formation and treatment of clinical cancer has been extensively 
reviewed (11, 14–17). The evidence for cancer immune surveil-
lance comes from animal studies, epidemiologic observations, 
and clinical observations.
Animal Studies
The original immune surveillance hypothesis was experimentally 
tested in a nude mice model in the 1970s by Stutman at Memorial 
Sloan Kettering Cancer Center in New York. The expectation was 
that immunodeficient (athymic nude) mice should develop more 
spontaneous and carcinogen-induced tumors than their immu-
nocompetent counterparts. Stutman’s experiments, however, did 
not yield results to validate these predictions (18, 19). Stutman’s 
study concluded, correctly, that their results argued against the 
thymus dependency of immunologic surveillance (19). The nude 
mice model was good as a T-cell-deficient model, but it was later 
recognized that they still had active natural killer (NK) cells and, 
therefore, were not completely immunodeficient (20). These 
results resulted in shelving of the cancer immune surveillance 
hypothesis for a while until a new series of experiments provided 
strong support in the 1990s. It is now well documented that the 
immune system has a critical role in controlling the development 
of not only virally induced tumors but also non-virally induced 
tumors (14, 21, 22).
In the modern experiments, when mice genetically engi-
neered to be deficient for various components of the immune 
system were assessed for the development of carcinogen-induced 
tumors, it was observed that tumors arose more frequently and/
or grew more rapidly in the immunodeficient mice relative to 
immunocompetent controls. In particular, deficiencies in the 
development or function of CD8+ cytotoxic T  lymphocytes 
(CTLs), CD4+ Th1 helper T  cells, or NK  cells each led to 
demonstrable increases in tumor incidence; moreover, mice 
with combined immunodeficiencies in both T cells and NK cells 
were even more susceptible to cancer development. The results 
indicated that, at least in certain experimental models, both the 
innate and adaptive cellular arms of the immune system are 
able to contribute significantly to immune surveillance and thus 
tumor eradication (23–25).
In addition, cancer cells from immunodeficient mice are not 
capable of initiating tumors in other immunocompetent hosts, 
but cancer cells from immunocompetent mice can initiate 
transplanted tumors in immunocompetent or immunodeficient 
hosts (23, 24). Such behavior has been interpreted as follows: 
highly immunogenic cancer cell clones are eliminated in 
immunocompetent hosts by the process of immunoediting with 
weakly immunogenic variants continuing to grow. Those weakly 
immunogenic cells giving rise to the tumor can also colonize 
other hosts both immunodeficient and immunocompetent. In 
immunodeficient hosts, however, the immunogenic cancer cells 
are not selectively eliminated and can survive the non-existing 
immunoediting process. When cells from tumors not subjected 
to immunoediting are transplanted into other genetically iden-
tical hosts, the immunogenic cancer cells are rejected by the 
competent immune systems of the new hosts (26).
When the host is immunocompetent and the tumor is immu-
nogenic, cancer immune surveillance works most efficiently. 
This combination results in an active immune system as evident 
in the tumor microenvironment and also as systemic antibody 
response against the tumor antigens. Systemic response and its 
positive correlation with clinical outcome have been observed in 
colorectal cancer (antibodies against carcinoembryonic antigen), 
pancreas cancer [antibodies against mucin 1 (MUC1)], anaplastic 
large cell lymphoma (antibodies against anaplastic lymphoma 
kinase), and lung cancer (antibodies against zinc-binding α2-
glycoprotein-1) (27). The constitution of the immune cells in the 
tumor microenvironment also correlates with clinical outcome. 
The stronger the tumor-specific immune response, the better the 
outcome (14, 16, 21, 27–32).
The modern experiments resulted in that a whole series of 
phases in the interaction of the immune system and cancer make 
up the “immunoediting” process. These phases are elimination, 
equilibrium, and escape (11, 17, 33). Immunoediting process 
eliminates highly immunogenic tumors in their early phases 
and selects for less immunogenic ones allowing their escape 
from elimination. This happens both before (34) and after (35) 
treatment. It is the neoantigens derived from somatic mutations 
in tumors that provide the link between the adaptive immune 
system that mounts specific immune response and cancer 
elimination. The immunologic pressure against neoantigens is 
the reason for both immunological control (early) and escape 
from this control (late) in cancer development. Direct support for 
the immunoediting process also came from the observation that 
the more immunodeficient the host is, the more immunogenic 
their tumors are (17).
The immune system may also be a double-edged sword and 
act to induce or promote cancer via inflammation (36, 37). Either 
infection or autoimmunity-induced, or due to the lack of physi-
cal activity or obesity, chronic inflammation is a well-established 
risk factor for cancer development. Chronic inflammation is a 
feature of aging and increases the risk for cancer development, 
progression, and metastasis by generating a tumor-supporting 
microenvironment. Inflammation is recognized as a factor that 
fosters multiple cancer hallmark functions (38). Cancer’s abilities 
to thrive in a chronically inflamed microenvironment, evade 
immune recognition, and suppress immune reactivity are also 
named as three immune hallmarks of cancer (39).
epidemiologic Observations
Epidemiologic studies have provided strong evidence for the con-
trol of cancer formation and control by the immune system. The 
earliest observation was that people with a weakened immune 
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system have higher cancer incidence rates. At least some of pri-
mary immunodeficiencies confer increased cancer risk (8, 40). 
Acquired immunodeficiencies or immunosuppression as happens 
in organ transplant recipients and HIV infection has increased 
risk for cancer (8, 41, 42). Although earlier studies only observed 
an increased risk for infection-related cancers, later and larger 
studies show an increased risk for non-infection-related cancers 
(42). Some immunosuppressed organ transplant recipients have 
been observed to develop donor-derived cancers, suggesting that 
in the ostensibly tumor-free donors, the cancer cells were held in 
check, in a dormant state, by a fully functional immune system 
(43). These observations provide examples for the elimination 
phase of the modern immunoediting process.
There is also evidence for the equilibrium phase. A convinc-
ing number of studies on people died of non-cancer causes have 
revealed a high degree of occult cancers in otherwise healthy 
individuals (44). Few specific examples are as follows: in 110 
consecutive autopsies of women aged 20–54 years, 22 were found 
to have evidence of breast cancer (only 1 had a history of cancer). 
Of these, 45% had multifocal and 41% had bilateral evidence for 
cancer presence (45). Another study noted the presence of cancer 
in opposite breast in 80% of women who died with a clinical 
diagnosis of breast cancer (46).
Unexpectedly high in situ prostate cancer rates were also found 
in men. An evaluation of 152 prostate glands from young males 
aged 10–49 years, up to 44% of them (in the fifth decade of age) had 
microscopic evidence of prostate cancer with an increasing age-
related incidence (47). In Hungary, incidental prostate cancer was 
found in 38.8% of 139 men aged 18–95 years, and there was also 
an age-related increase (48). A larger study examined 340 pros-
tates harvested from organ donors and detected adenocarcinoma 
in 12% of them also with an age-dependent increase, leading to 1 
in 3 chance of carrying incidental cancer in the 60- to 69-year-old 
age group and even higher (46%) in 70- to 81-year-old men (49). 
One study compared incidental prostate carcinoma rates between 
Russian (n = 220; mean age = 62.5 years) and Japanese (n = 100; 
mean age = 68.5 years) men in autopsy samples. Prostate cancer 
was detected in 37.3% of Russian and in 35.0% of Japanese men 
overall, with the cancer rates reaching more than 40% of men 
aged greater than 60 years and nearly 60% in men aged above 
80  years (50). The prevalence of latent prostate cancer is well 
above 2.9% lifetime risk of dying from prostate cancer (51).
The autopsy findings in breast and prostate cancers suggest 
that our bodies harbor many more cancers than those become 
clinically evident [so-called cancer without disease (52)]. One way 
to interpret this observation is that most tumors are kept at equi-
librium by the immune system. This interpretation also applies to 
the finding that pancreas cancer takes more than two decades to 
become metastatic and detectable (53). A similar phenomenon 
is reported for dormant melanoma in the mouse in which it was 
established that tumor cells disseminate early, but immunosur-
veillance limits metastatic outgrowth (54). There are, however, 
alternative interpretations involving angiogenesis pathways (52, 
55). Thus, the reasons for the observations of dormant cancers 
at frequencies much higher than actual cancer incidence rates 
may include immune control, but this has not been specifically 
examined. Tumor dormancy as a result of endogenous immune 
surveillance is better documented for metastatic cells (54, 56), but 
there is currently no direct evidence for the role of the immune 
system in restriction of primary tumor growth in humans. This 
is, therefore, an area where future research may shed some light.
Clinical epidemiology also increasingly supports the exist-
ence of anticancer immune responses in some forms of human 
cancer (14, 16, 21, 27, 29–32). For example, patients who have 
cancer, especially colon and ovarian cancers, and who are heavily 
infiltrated with CTLs and NK cells have a better prognosis than 
those who lack such abundant killer lymphocytes.
Epidemiologic studies also suggested that otherwise healthy 
people with lower immune-mediated NK  cell-mediated cyto-
toxic capacity develop more cancers in follow-up, and there is 
a genetic component in this correlation (57, 58). This is just 
additional evidence that NK  cells play a critical role in the 
recognition and eradication of tumors (59). In experimental 
animal models, NK cell deficiency increases cancer occurrence 
just like observed in Chediak–Higashi syndrome character-
ized by abnormal NK cytotoxic function. Importantly, natural 
cytotoxicity correlates with lifestyle factors known to modify 
cancer susceptibility (60, 61). Among the statistically significant 
observations, smoking (negative effect on NK  cell activity), 
green vegetable consumption, and regular sleeping (positive 
effect) (60) as well as personality types (61) were noteworthy. 
A separate study reported favorable effect of beta-carotene on 
NK cell function in the elderly (62).
Clinical Observations
The strongest evidence for cancer immune surveillance comes 
from the incredible success of cancer immunotherapy, which has 
revolutionized cancer treatment. The Science magazine named 
cancer immunotherapy as the Breakthrough of the Year for 
2013 (63). Besides cancer immunotherapy becoming a routine 
treatment choice, there are more than a dozen drugs or vaccines 
approved by the US Food and Drug Administration for cancer 
prevention (64). Cancer immunoediting, beginning with cancer 
immune surveillance and elimination and ending with escape, 
is now firmly established as a reality. As a result, escape from 
immune control (immunoevasion) is now one of the emerging 
hallmarks of cancer (38).
The success of immunotherapy comes from its ability to break 
down the immunoevasion caused by the tumor cells. Tumor cells 
interfere with the immune response against tumor antigens by 
releasing molecules, which are normally used by the immune 
system to self-limit the activation. Once the antigen receptors 
(T-cell receptors) are engaged with the antigen, in this case 
tumor antigen, T-cells also require an activation signal from the 
costimulatory molecule CD28 to become effective killer cells. It 
is the B7 molecule on the antigen-presenting cell that activates 
the costimulatory molecule CD28 on T cells. T cell activation is 
required for immune response but should be controlled to avoid 
overactivation and autoimmunity. Once activated, T  cells start 
expressing coinhibitory immune checkpoint molecules, cytotoxic 
T lymphocyte-associated antigen 4 (CTLA-4), and programmed 
death 1 (PD-1) (65). Engagement of these molecules with B7 
generates inhibitory signals for T cells. Tumor cells inhibit T cells 
and evade immune response against them by releasing such 
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coinhibitory molecules. For the purpose of cancer immuno-
therapy, monoclonal antibodies have been generated to counter 
these inhibitory signals. This is achieved by “immune checkpoint 
blockade” of CTLA-4, PD-1, or PD-1 ligand (PD-L1). These are 
monoclonal antibodies known as ipilimumab (an inhibitor of 
CTLA-4), nivolumab and pembrolizumab (inhibitors of PD-1), 
and atezolizumab and durvalumab (inhibitors of PD-L1) (65). 
The success of these immune check point blockers is strong evi-
dence for the involvement of the immune system in the control 
of cancer development.
Another clinical observation is that agents used in cancer pre-
vention or treatment may stimulate the immune system. This is 
likened to “the invisible arm of immunity” acting alongside their 
cytotoxic effects. The chemoprevention agents such as repur-
posed drugs such as aspirin, COX-2 inhibitors (e.g., celecoxib), 
the antidiabetic agent metformin, the bisphosphonate zoledronic 
acid, and tamoxifen (and aromatase inhibitors) used in cancer 
prevention also show immune activity [reviewed in Ref. (32, 66)]. 
Another more experimental chemopreventive agent curcumin 
also has immunologic effects (32, 67). Likewise, the antitumor 
effects of many conventional cancer treatments also involve the 
immune system. They promote immunogenic tumor cell death 
or directly stimulate immunoeffector cells (27, 31, 32, 68). The 
immunologic effects include enhancing the antigen-presenting 
cell (mainly dendritic cells) activity and cross-presentation of 
tumor antigens to CD8+ T-cells (e.g., methotrexate), increasing 
HLA class I antigen expression (e.g., gemcitabine, oxaliplatin, 
cyclophosphamide), favorable modification of helper T-cell 
polarization, and inhibition of immuno suppressor cells [mainly 
FOXP3+  T  regulatory (Treg) cells, and myeloid-derived sup-
pressor cells (MDSCs)] (e.g., vincristine, docetaxel, paclitaxel) 
(16, 32). These observations even led to a new form of cancer 
treatment using low doses of conventional chemotherapeutic 
agents (metronomic chemotherapy) to stimulate the immune 
system as opposed to suppressing as they do at their usual doses 
(27). In fact, methotrexate is such a strong immunosuppressive 
so that it is also used to treat autoimmune disorders but is used 
as an immunostimulant at lower doses.
MOST CANCeR RiSK FACTORS OPeRATe 
VIA THe iMMUNe SYSTeM
environmental Risk Factors
Age and Sex
Age is one of the strongest risk factors for cancer development. 
It is reported that the mortality rate increases 43 times for 
cancer in people older than 65 years in Western countries (69). 
An examination of the US SEER Database (2009–2013) shows 
that the median age at diagnosis for all cancers is 65 years, and 
median age at death from cancer is 72 years (https://seer.cancer.
gov/statfacts/html/all.html). Cancer occurs more frequently 
with increasing age due to cumulative exposures to carcinogenic 
agents such as tobacco, infectious agents, and chemicals, as 
well as due to physiologic changes in the body due to hormonal 
changes and immune system dysregulation. Among the physi-
ologic changes, immunosenescence, which can be described 
as progressive decline of the immune functions, alongside 
qualitative and quantitative dysregulations involve both innate 
and adaptive arms of immunity (12, 70–74). Some of the con-
sequences of immunosenescence with aging like reactivation of 
persistent viral infections (such as varicella zoster virus) are well 
recognized. Conversely, it is the persistent viral and parasitic 
infections that contribute to the loss of immunosurveillance 
via premature exhaustion of T  cells (70). Overall, infections, 
cancer, and autoimmune diseases are more frequent in the 
elderly, and all are related to the changes in the immune system 
(71, 73). Most crucially, bone marrow hematopoietic stem cells 
skew toward myelopoiesis (and against lymphopoiesis) with 
age, which leads to increased numbers of MDSCs (73, 75). 
The increase in MDSC numbers show correlations with cancer 
incidence in the elderly (73, 75). Certain lifestyle factors may 
potentially contribute to age-associated unfavorably changes 
in immunity in the elderly, including psychosocial parameters, 
stress responsiveness, physical inactivity, and nutritional factors 
(76). Some of the age-related immune system changes in the 
elderly may be reversed by simple lifestyle modifications (76, 
77), including aerobic exercise (78), which is further discussed 
below. Further, a lot of pharmacologic ways to rejuvenate the 
aging immune system are also present (72, 79), but none is in 
current routine use yet.
Sex is another consistent risk factor for cancer (80, 81). Sex 
effect is likely to operate through immune surveillance differ-
ences between the sexes (12, 82). Thus, like age, sex is another 
consistent risk factor that seems to operate via the immune 
system.
Lack of Physical Activity
Health benefits of regular and moderate intensity physical 
activity are not restricted to improvements in metabolic and 
cardiorespiratory function for prevention of type 2 diabetes 
and cardiovascular diseases. Physical activity also decreases 
the risk for various cancers by several mechanisms, including 
decreased sex hormones, metabolic hormones and inflam-
mation, and quantitative and qualitative changes in immune 
cells (77, 83). Research on the effect of aerobic exercise on 
the immune response has confirmed the skeletal muscle as 
an endocrine organ capable of secreting cytokines, which 
are called “myokines.” Exercise modulates the host immune 
response via skeletal muscle–organ cross talk (84–86). Regular 
physical activity appears to have immunoenhancing effects via 
improved neutrophil microbicidal functions, which reduce the 
risk of infectious disease, and increased immune cell telomere 
length (77, 78, 87). Negative energy balance induced by exercise 
also exerts anti-inflammatory effects by reducing chronic low-
grade inflammation (77, 88). Overall, the evidence for a causal 
association between physical activity and colon and breast 
cancers is strongest and somewhat weaker for prostate, lung, and 
endometrial cancers and insufficient for testicular and ovarian 
cancers (89, 90). As a result, more breast and colon cancers than 
coronary heart disease can be prevented by regular physical 
activity (90, 91). It has been estimated that up to 330,000 cases of 
6 major cancers could have been prevented with regular physical 
activity at the recommended level in Europe in 2008 (90).
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Obesity
Obesity is responsible up to 20% of cancer mortality (92). Both 
local and systemic mechanisms are involved in the mediation 
of increased cancer risk, and these include the immune system 
alterations associated with obesity (12). Like the muscle is now 
considered an organ, the adipose tissue is an active endocrine 
organ, and like myokines from the muscle, adipokines are 
released from the fat tissue, which target organs including 
the immune system (93, 94). Overall effects of obesity on the 
immune system can be summarized as direct negative effect 
of the major adipokine leptin on immune cells; induction of 
chronic systemic inflammation via secretion of pro-inflam-
matory adipokines; acceleration of the aging of thymus, an 
important immune system organ; adversely affect the function 
of the primary immune organs bone marrow and thymus via 
infiltration of fat tissue; and reduced immune response to infec-
tious agents (12). In particular, the involution of the thymus 
with age and lower production of naive T  cells contribute to 
lower immune surveillance in the elderly. It has been shown 
that obesity accelerates thymic involution resulting in lower 
T cell numbers (95). Therefore, obesity is another cancer risk 
factor that acts, among other mechanisms, through alterations 
it causes in the immune system.
Diet
The influence of dietary factors in the development of chronic 
diseases, including cancer, is well known. What is not that well 
known is the role of diet in predisposition to cancer via immune 
system modulation and anti-inflammatory effects (96). Candidate 
nutrients with immunomodulatory effects include essential fatty 
acids; antioxidants; calcium; zinc; selenium; vitamins A, D, 
B6, and folate; omega-3 polyunsaturated fatty acids (omega-3 
PUFAs); glutamine; arginine; S-amino acids; nucleotides; poly-
phenols; epigallocatechin gallate; beta-glucans; isothiocyanates; 
curcumin; and probiotics, which make up immunonutrient 
mixes (96–98). Caloric restriction and protein calorie balance 
have also been reported to have some immunomodulatory 
effects. Unfortunately, despite some data from observational 
and animal studies, there are only limited data from randomized 
clinical trials (RCTs). A cohort study examined the effects of 
high marine omega-3 PUFAs intake on colon cancer occur-
rence and clinical status and reported a very favorable outcome 
with detectable improvement on the immune response to the 
tumor (99). A double-blind RCT explored the effectiveness of 
a commercially available immunomodulating enteral nutrition 
formula (Impact®, Nestlé) in radiochemotherapy-treated head 
and neck and esophageal cancer patients (100). By phenotyping, 
functional assays, and gene expression analysis, clear immu-
nostimulation was noted although clinical correlates were not 
reported. Most interestingly, even cancer preventing effect of 
fiber may be due to its indirect effect on the immune system. 
High-fiber diet consisting of starch, cellulose, pectin, or fructan 
induce the gut microbiota to produce short-chain fatty acid 
metabolites (acetate, butyrate, propionate), which in turn stimu-
late Treg cells for expansion and immune-suppressive properties 
to control pro-inflammatory responses in the gut (101). Clinical 
correlates of this observation are yet unknown, but high-fiber 
diet may have an immunomodulatory component in its cancer 
preventive effects.
Smoking
Smoking and cancer connection is well established and is due 
to the carcinogenic content of tobacco products. The overall 
effects of smoking on the immune system is to weaken the 
immune system via a pro-inflammatory reaction and suppres-
sion of effector functions of immune cells as well as skewing 
of the immune response toward Th2 type (102) although the 
effect on cytokine production seems negligible (103). Cytotoxic 
T  cells, NK  cells, and macrophages are among important 
immune cells that are suppressed by smoking. It is probable that 
immune system alterations complement smoking-associated 
carcinogenic and mutagenic effects in the causal pathway to 
cancer development.
Childhood Infections and Future Cancer
Recurrent infections may show seemingly inconsistent correla-
tions with future cancer risk. If recurrent infections are due to 
immunodeficiency, childhood cancer risk may be increased as a 
result of insufficient immune surveillance (104), but if they are 
community-acquired natural infections, these infections may 
help development of the immune system and subsequently pre-
vent childhood cancer development (105). An abnormal immune 
response by an underdeveloped immune system to a common 
infection because of a delay in infectious exposure is also a pos-
sibility (106), which is known as the Greaves hypothesis proposed 
to explain the childhood leukemia occurrence most commonly in 
the age peak (2–5 years old).
The more interesting observations concern the lower risk of 
adult cancer following certain childhood infections (12). It has 
been observed that infections such as chicken pox, measles, 
pertussis, and mumps may lower the risk for a number of adult 
cancers, especially ovarian cancer (107, 108). This is attributed 
to molecular mimicry in which microorganisms causing these 
infections have certain antigens (such as MUC1) that induce a 
lifelong immunity, which then recognizes the same antigen on 
cancer cells. The preexisting immunity against tumor antigens 
due to cross-reactivity facilitates immune surveillance, and 
cancer would be prevented. An altered form of the tumor antigen 
MUC1 is frequently expressed in ovarian cancer, and immunity 
against MUC1 is formed by mumps infection, which results in the 
observed inverse correlation between mumps and ovarian cancer 
(107, 108). It is now a possibility that upward trends in cancer 
incidence may be contributed by the mass vaccination campaigns 
and fewer infectious episodes in childhood.
Reproductive Factors
Nulliparity is a strong and consistent risk factor for breast, ovar-
ian, and endometrial cancers, whereas early full-term pregnancy 
and parity confer a significant protection. The mechanism is 
thought to involve local hormonal effects on these organs, but 
there appears to be an immune system involvement too (12). 
Comparative molecular studies in breast tissue have shown that 
the gene expression signature differences between nulliparous 
and multiparous women as well as between pregnancy and 
TAbLe 1 | immune regulatory gene polymorphisms and cancer susceptibility in GwAS and GRASP catalogs.
Genetic variants Main non-cancer associations Cancer associations Reference 
[PubMed iD 
number (PMiD)]a
Genetic variants regulating immune 
cell levelsb
Autoimmune disorders (type 1 
diabetes, rheumatoid arthritis)
Neuroblastoma (rs6547705; P = 2.0E−02) 21124317
Genetic variants correlated with 
immune traitsc
Autoimmune disorders (ulcerative 
colitis); hemoglobin A2 level
Neuroblastoma (rs10917750; P = 5.8E−04—rs723177; 
P = 9.6E−04—rs4657090; P = 1.2E−03—rs1934908; P = 3.8E−03)
Prostate cancer (rs12359272; P = 8.2E−03)
21124317
23668334
Immunoregulatory gene variants 
associated with cancer risk in 
candidate gene studiesd
Autoimmune disorders (rheumatoid 
arthritis, Crohn disease)
Non-melanoma skin cancer (rs12203592; P = 7.2E−14) 23548203
Melanoma (rs12203592; P = 2.5E−05) 20602913
Neuroblastoma (rs12203592; P = 4.9E−05) 21124317
Breast cancer (rs12203592; P = 2.7E−06) 20453838
Hodgkin lymphoma (rs2395185; P = 4E−31) 22286212
Lung cancer (rs2395185; P = 9.5E−10) 23143601
Acute lymphoblastic leukemia (rs17007695; P = 9E−07) 19176441
Childhood acute lymphoblastic leukemia (rs5742909, P = 8E−04) 20189245
Breast cancer (rs2296135, P = 3.7E−03) 23468962
Non-Hodgkin lymphoma (rs1041981; P = 1.9E−02) 21471979
aFor cancer associations shown (PMID).
bRef. (120) (SNPs listed in Supplementary Tables 5 and 6 in the original paper, n = 109. The SNP list is available in Table S1A in Supplementary Material in the present paper).
cRef. (119) (SNPs listed in Table 1/Supplementary Table 5 with P < 5E−10 in the original paper; n = 709. The SNP list is available in Table S1B in Supplementary Material in the 
present paper).
dThe SNPs included in the analysis here are listed in Table S1C in Supplementary Material.
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postpregnancy included those of immune surveillance genes 
(109, 110). It has also been proposed that pregnancy increases 
the exposure of women to fetal antigens and induces immunity 
against them, which may be targeted against cancers expressing 
fetal antigens (111). Equally, a greater number of ovulatory cycles 
increase the risk for ovarian, breast, endometrial, pancreas, and 
colon cancers and correlate with lower anti-MUC1 antibodies 
(107).
Other Environmental Cancer Risk Factors
Other connections of the immune system to cancer risk fac-
tors include pesticides (112), benzene (113), arsenic (114), 
ultraviolet irradiation (115) exposure, and psychological stress 
(116, 117).
Genetic Risk Factors
Genetic variation is instrumental as the origin of variation 
observed in many traits. Formally, the contribution of heritable 
genetic variation to the phenotypic variance observed is measured 
by heritability, which lies between 0 and 100%. Heritability can 
be quantified in twin studies. Such a study of immune parameters 
concluded that heritability was less than 20%, and a great majority 
of examined parameters (>75%) were dominated by non-herit-
able, i.e., environmental, influences (118). Another twin study 
examined 78,000 immune traits of which 1,800 were independent 
and were subjected to a genome-wide search for genetic correlates 
(119). We have subjected known genetic markers of immune 
parameters (119, 120) to a cross examination against the existing 
genome-wide association studies (GWAS) result databases to 
see whether any of them is a cancer risk marker. As shown in 
Table 1, this effort only revealed very weak cancer associations in 
GWAS. When we repeated the same analysis with immunoregu-
latory gene SNPs reported to be associated with cancer risk in 
candidate gene studies, we observed stronger GWAS associations 
although not replicating the originally observed associations 
(Table 1). Thus, we could only obtain limited evidence for the 
involvement of immune system-related genetic polymorphisms 
in the modification of cancer risk. This result is not necessarily 
surprising given that GWAS cannot readily capture gene–gene 
or gene–environment interactions (121), which are probably 
more relevant to the immune system. Since most cancers result 
from the combined effects of environmental factors and inherited 
susceptibilities and that only a few cancers are “solely” of genetic 
origin. The importance of the environment in cancer causation 
has implications for studies of genetic risk in cancer that is not 
sufficiently appreciated (122).
Cumulative evidence for immune surveillance against the 
development of cancer and for the control of existing cancer is 
listed in Table 2.
iMMUNOPReveNTiON OF CANCeR AS  
A PUbLiC HeALTH iNTeRveNTiON
An immunologic approach to cancer prevention is not new 
(128). Most of the general cancer prevention approaches 
including elimination of environmental hazards (e.g., smok-
ing), lifestyle changes (e.g., increased physical activity, healthy 
and balanced diet with green vegetables), chemopreventive 
agents in high-risk individuals, and obviously immunopreven-
tion via vaccination [e.g., hepatitis B virus (HBV) and human 
papilloma virus (HPV) vaccination] target the immune system 
at least partially.
TAbLe 2 | evidence for immune surveillance against the development of 
cancer and for the control of existing cancer.
Observation implication Referencea
Immunodeficient animals and 
humans developing more cancers; 
immunosuppression causing an 
increase in cancer incidence
Control of cancer 
development by the 
immune system
(8, 40, 42, 
123)
Increased risk for cancer in people with 
lower natural cytotoxic activity in their 
peripheral blood
Control of cancer 
development by the 
immune system
(57, 58)
A high percentage of occult cancers in 
autopsy studies
Control of cancer at 
the preclinical stage 
by the immune system 
(equilibrium)
(44–50)
Decades long time taken by pancreas 
cancer to become clinically overt
Control of cancer at the 
preclinical stage by the 
immune system
(53)
Control of occult cancer at the 
equilibrium phase by adaptive immune 
system
Control of cancer at the 
preclinical stage by the 
immune system
(124, 125)
Development of donor-derived 
malignancies that have been kept 
under control in immunosuppressed 
transplant recipients
Control of cancer at the 
preclinical stage by the 
immune system
(43)
More immunogenic tumors developing 
in more immunodeficient animals
Elimination of 
immunogenic tumors 
by immune competent 
hosts
(17, 124, 126)
Cancer patients with antibodies 
against antigens of their tumors (e.g., 
carcinoembryonic antigen, mucin 1) 
having a better clinical outcome and 
even spontaneous regression
Existent antitumor 
immunity exerting a 
favorable effect on the 
outcome
(27, 31, 127)
Successful chemopreventive agents 
(aspirin, metformin, tamoxifen, 
bisphosphonate) having immune 
enhancing effects
Contribution of the 
immune system to the 
preventive effects
(32, 66)
Successful cancer chemotherapeutic 
agents having immune modulatory 
effects favorable for anticancer 
immunity
Contribution of the 
immune system to the 
therapeutic effects
(27, 31, 32, 
68)
The composition of tumor-infiltrating 
immune cells and indicators of immune 
system activity correlate with the 
clinical outcome
Existent antitumor 
immunity exerting a 
favorable effect on the 
outcome
(14, 16, 21, 
27–32)
aIn some instances, review papers rather than primary references are cited.
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Specifically, immunoprevention aims to prevent cancers 
through the use of vaccines against carcinogenic viruses and 
tumor antigens, antibodies against immune molecules, and 
immune modulators (30). While vaccines against tumor antigens 
and antibodies are used in individuals with a specific cancer, 
immune modulators have more broad activities to enhance 
natural cancer immune surveillance. HBV and HPV vaccina-
tions are approved interventions against liver and cervical cancer 
caused by these viruses, respectively. Pharmacologic immune 
modulators that are currently in use include aspirin, COX-2 
inhibitors, aromatase inhibitors, metformin, and bisphospho-
nates (32). Non-pharmacologic effects linked to lifestyle factors 
and environmental exposures reviewed in this article may have 
a wider application in primary prevention in people who do not 
yet have cancer. In fact, now that cancer is becoming the most 
common cause of death in developed nations (129), and it is 
important to increase awareness about immunoenhancement 
and cancer immunoprevention for everyone’s benefit (78).
Immunoenhancement is a very active area of research (76–78, 
87) with some emerging results (128). Among the non-pharma-
cologic interventions to enhance the immune system, physical 
activity, dietary factors, and lifestyle changes are the best-known 
ones, and the use of immune modulation for prevention rather 
than therapy is becoming a reality (128).
Regular moderate physical activity is the most effective pre-
vention strategy for a number of chronic diseases. Despite being 
very affordable, it is probably the most underutilized intervention. 
While the impact of physical activity on cardiovascular system is 
well recognized and a lot of interventions are implemented to 
enhance cardiovascular health, its connection to the immune 
enhancement and cancer prevention is not known as much. This 
is despite that the impact is actually greater on cancer preven-
tion although this is not exclusively due to immune-enhancing 
effects (90, 91). Despite calls for exercise clinical trials in cancer 
prevention research (130, 131), more progress has been recorded 
in clinical trials on the effect of exercise on clinical outcome and 
survivorship of cancers than their prevention (132, 133). Since 
the evidence is strongest for colon and breast cancers (89, 90), at 
least for these ones, the modulation of the immune system with 
an exercise program may be used to enhance prevention and 
treatment outcomes (86). As mentioned above, physical activity is 
also effective in reversing age-related deterioration in the immune 
system (78). Typically, as we age, physical activity levels decline. 
Among the reasons for this are the lack of motivation for physical 
activity and unawareness of the health benefits, while awareness 
of unhealthy lifestyle, perceived susceptibility to disease as well as 
motivation towards lifestyle changes are important mediators of 
participation in lifestyle interventions (134).
After physical activity, nutritional modifications have the 
strongest immunomodulatory effects that may be used as a 
public health intervention (78). Flavonoids (such as green tea) 
are well known for their cancer preventive properties, which are 
due to epigenetic modifications (135). Quercetin, for example, 
is proposed as a preventive dietary factor for melanoma (136), 
and green tea is an acknowledged cancer preventive agent in 
Japan (137). A positive effect of all flavonoids is modulation of 
the immune system (138). Thus, flavonoids, including green tea, 
can be considered as safe cancer immunopreventive agents for 
general use. Fiber- and green vegetable-rich diet is also safe for 
general use for their cancer preventive properties, which include 
immune enhancement. Dietary supplements mentioned above, 
including beta-carotene and vitamin E, are suggested as immu-
nomodulatory agents, but confirmatory evidence from clinical 
trials is currently missing. Until then, the recommendation of 
the American Institute for Cancer Research of not to take any 
supplements for cancer prevention should be adhered to.
Although RCTs are regarded as the source of strongest evi-
dence to support clinical decisions, increased trial complexity 
and cost may be inhibitory and may explain the scarcity of such 
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trials in cancer immunoprevention studies. Recently popularized 
pragmatic clinical trials represent a new approach for enhancing 
the evidence base by relaxing the strict regulations governing 
RCT conduct (139, 140). These trials are more widely accessible 
by participants, are less resource intensive, and place minimal 
burden on participants. Pragmatic trials are designed to test 
the effectiveness of usually non-pharmacologic intervention in 
routine practice and whether an intervention actually works 
in real life. They, therefore, generate evidence with a greater 
external validity. Besides pragmatic trials, other more practical 
approaches such as systems science methods are also available 
as alternatives and have already been used to answer important 
public health science questions (141). Thus, implementation of 
cancer immunopreventive strategies as public health interven-
tions may be expedited using research methods emerging as 
alternatives to RCTs.
While cancer immunotherapy has revolutionized cancer treat-
ment, cancer immunoprevention using vaccines and chemopre-
ventive agents for selected high-risk people is also moving into 
the clinics (1, 66). Recent technological developments herald a 
new era in cancer detection and management that will also neces-
sitate public health interventions. Soon, there will be more people 
under active surveillance than ever before, and recommendations 
to these people may include lifestyle modifications to maintain a 
healthy immune system as well as personalized risk stratification 
based on the assessment of their immune system. Preventing can-
cer in otherwise healthy, asymptomatic, and unsuspecting people 
will need to be carefully considered. If lifestyle modifications to 
enhance immune surveillance to prevent cancer sounds like a 
far-fetched idea, one has to remember the recent success stories 
in cardiovascular disease prevention by the same approach (142). 
Cancer-related mortality is beginning to exceed cardiovascular 
disease-related mortality in some European countries (143) and 
US states (129), and primary prevention is the most effective 
way to fight cancer (144). With more than 50% of cancers are 
hypothetically preventable through lifestyle modifications (145), 
the aim should be to increase this proportion with the implemen-
tation of cancer immunoprevention strategies in the near future.
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